The Patent Cliff: $230 Billion in Drug Savings Coming by 2030

What Is the Patent Cliff?

The "patent cliff" refers to the sharp revenue drop that pharmaceutical companies face when their blockbuster drugs lose patent protection. Once a patent expires, generic manufacturers can produce the same drug at a fraction of the cost — typically 80-95% cheaper within a few years. For biologics, biosimilar competition delivers savings of 15-85% depending on market dynamics.

The 2025-2030 patent cliff is unprecedented. Seven of the top 10 best-selling drugs in the world are losing exclusivity during this period, representing over $230 billion in combined annual revenue. The Inflation Reduction Act's Medicare drug negotiation program is accelerating savings on several of these drugs even before full generic entry.

Key Drugs Losing Patent Protection

Januvia/Janumet (sitagliptin) — Generic May 2026

Merck's diabetes franchise generated $2.7 billion in Medicare Part D spending annually. Januvia loses patent protection in May 2026, with multiple generic manufacturers ready to launch. Patients paying $500+ per month for brand Januvia could see costs drop to $50-100 once generics are widely available.

Eliquis (apixaban) — 43% Medicare Cut + Generics Coming 2028

Eliquis is the single most expensive drug for Medicare, with $16.6 billion in annual Part D spending. The Inflation Reduction Act negotiated a 43% price reduction effective 2026 for Medicare patients. Full generic competition is expected by 2028 when the last patents expire, which should push prices down even further. Bristol-Myers Squibb and Pfizer have fought to protect this franchise, but the patent wall is crumbling.

Stelara (ustekinumab) — 9 Biosimilars Already Launched

Johnson & Johnson's Stelara saw its biosimilar floodgates open in 2025. Nine biosimilars are now available, and Medicare negotiated a 66% price cut under the IRA. Some biosimilars are already discounted up to 90% off the reference price. With $7.2 billion in Medicare spending, the savings here are enormous for patients with psoriasis, Crohn's disease, and other autoimmune conditions.

Humira (adalimumab) — 22 Biosimilars Available

Once the world's best-selling drug, Humira now faces competition from 22 biosimilars after AbbVie's patent wall finally fell in 2023. Price reductions have been uneven — ranging from 5% to 85% off the original price — because pharmacy benefit managers and insurers negotiate different deals. Medicare spending was $4.3 billion, and patient out-of-pocket costs are falling as biosimilar adoption increases.

Entresto (sacubitril/valsartan) — Patent Expiry Approaching

Novartis's heart failure drug Entresto generated $4.8 billion in Medicare Part D spending. Patents begin expiring in 2026-2027, and generic manufacturers are already preparing applications. For the millions of Americans with heart failure, this could mean savings of $3-4 billion annually once generics are widely available.

Keytruda (pembrolizumab) — Patent Expiry ~2028

Merck's cancer immunotherapy Keytruda is the world's best-selling drug with over $25 billion in global revenue. Patent expiration around 2028 puts this entire revenue base at risk. As a biologic, Keytruda will face biosimilar rather than generic competition, but the savings potential is still massive — Medicare alone spent $10.2 billion on this drug. Merck is developing a subcutaneous version to try to maintain market share.

Revlimid (lenalidomide) — Generic Entry Happening

Bristol-Myers Squibb's multiple myeloma drug Revlimid had $7.8 billion in Medicare spending. Generic versions began entering the market in 2022 under volume-limited licenses, but unrestricted generic competition is now underway. Prices are expected to drop 80-85% as multiple generic manufacturers scale production.

Major Patent Expirations at a Glance

Full Generic Watch List

Our Generic Watch tracker monitors 25 drugs approaching patent expiry, ranked by Medicare spending impact:

View all 25 drugs on Generic Watch →

How Generics Cut Prices 80-95%

Generic drugs cost less because manufacturers don't need to repeat expensive clinical trials — they only need to prove bioequivalence to the brand-name drug. This typically costs $1-5 million compared to the $1-2 billion required to develop the original drug. The savings compound as more generics enter the market:

• 1 generic competitor: Prices drop ~40-50% from brand-name
• 2-3 generics: Prices drop ~60-70%
• 5+ generics: Prices drop ~80-90%
• 10+ generics: Prices can fall 95% or more (e.g., generic metformin costs under $4/month)

According to the FDA, generic drugs saved the U.S. healthcare system $408 billion in 2024 alone. The 2025-2030 patent cliff could add another $100-150 billion in annual savings once all the generics and biosimilars are fully available.

The Biosimilar Wave

For complex biologic drugs like Humira, Stelara, and Keytruda, the equivalent of a generic is called a biosimilar. Biosimilars are more complex to manufacture and require more extensive testing than small-molecule generics, which is why savings have historically been smaller (15-40% price reductions vs. 80-95% for generics).

But that's changing rapidly. The Stelara biosimilar market shows what's possible: with 9 biosimilars competing, discounts are reaching 85-90% off the reference price. The biosimilar tracker on DrugPrice monitors all approved and pending biosimilars and their real-world pricing.

Key biosimilar developments to watch:

• Humira biosimilars: 22 approved, adoption accelerating as formularies shift
• Stelara biosimilars: 9 launched, aggressive pricing competition underway
• Keytruda biosimilars: Multiple manufacturers preparing applications for ~2028 launch
• Eylea biosimilars: Competing products launching for wet macular degeneration

What This Means for Patients

If you're taking any of these blockbuster drugs, significant savings may be coming your way. Here's what to do:

• Ask your doctor if a generic or biosimilar is already available for your medication
• Check with your pharmacist — they can often substitute a generic without a new prescription
• Review your insurance formulary — many plans now prefer generics and biosimilars with lower copays
• Use our Generic Watch to track when your specific drug is expected to face generic competition
• For biologics, ask about interchangeable biosimilars — these can be substituted at the pharmacy just like generics

The patent cliff represents the single largest opportunity for prescription drug savings in history. With 507 drugs tracked on DrugPrice, you can look up any medication to check its patent status, generic availability, and cost trends.